• Study demonstrates Cantrixil’s potential to prolong survival in advanced ovarian cancer

Stockholm, Sweden, 30 June 2021 – Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, today announces that the results from a Phase I open-label study (NCT02903771) of the investigational drug candidate Cantrixil (TRX-E-002-1) have been published in Cancers, a peer-reviewed, open access journal of oncology. 

The paper entitled ‘Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results’ can be accessed online at the following link: https://www.mdpi.com/2072-6694/13/13/3196/pdf.

Oasmia acquired the exclusive global development rights for the Cantrixil ovarian cancer program from Kazia Therapeutics Ltd earlier this year. Top-line data from the Phase I study previously reported by Kazia Therapeutics Ltd in December 2020 and presented at the American Association of Cancer Research (AACR) annual meeting in April 2021 confirmed that the Phase I study met its primary endpoints, establishing clinical proof of concept.

The study was conducted at sites in the USA and Australia under the leadership of clinical trial’s Principal Investigator, Jermaine Coward, Associate Professor, ICON Cancer Centre, located in Brisbane, Australia. The study aimed to define the maximum tolerated dose, tolerability, and antitumor activity of Cantrixil when administered via an intraperitoneal (IP) port. Cantrixil was well tolerated even in patients with heavily pre-treated disease.

The study demonstrates the potential for prolonged survival in advanced ovarian cancer by inducing ovarian cancer stem cells’ death and sensitizing cancer cells to standard chemotherapy with IP-administered Cantrixil.

Dr. Heidi B. Ramstad, CMO of Oasmia, commented: “These data are encouraging and has demonstrated the potential for prolonged survival in some patients with advanced ovarian cancer. By inducing ovarian cancer stem cell death and sensitizing cancer cells to standard chemotherapy, Cantrixil may improve survival outcomes in this patient population. Ovarian cancer remains one of the most aggressive cancers and are proven difficult to treat in advanced stages. We look forward to the forthcoming Phase 2 trial investigating Cantrixil in combination with first-line chemotherapy with an aim to improve survival rates in ovarian cancer.”

For More Information: 

Oasmia Pharmaceutical AB 
Francois Martelet, Chief Executive Officer 
Phone: +46 18-50 54 40 
E-mail: IR@oasmia.com

Consilium Strategic Communications (For Oasmia)
Jonathan Birt, Chris Welsh, Ashley Tapp
Phone: +44 (0)20 3709 5700 
E-mail: oasmia@consilium-comms.com

About Oasmia Pharmaceutical AB
Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Oasmia’s most advanced program is Apealea® (paclitaxel micellar), which is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia’s proprietary drug delivery platform XR-17™ is designed to improve drug solubility, efficacy and safety. Oasmia’s shares are traded on Nasdaq Stockholm (OASM). To find out more about Oasmia please visit www.vivesto.com.